Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients - Comparison of cyclosporin and tacrolimus treatment

被引:18
|
作者
Wada, Kyoichi
Takada, Mitsutaka
Kotake, Takeshi
Ochi, Hiroyuki
Morishita, Hideki
Komamura, Kazuo
Oda, Noboru
Mano, Akiko
Kato, Tomoko
Hanatani, Akihisa
Nakatani, Takeshi
机构
[1] Natl Cardiovasc Ctr, Dept Pharm, Suita, Osaka 5650873, Japan
[2] Natl Cardiovasc Ctr, Dept Cardiol, Suita, Osaka 5650873, Japan
[3] Natl Cardiovasc Ctr, Dept Organ Transplantat, Suita, Osaka 5650873, Japan
[4] Kinki Univ, Sch Pharmaceut Sci, Div Clin Pharm, Higashiosaka, Osaka, Japan
关键词
heart; mycophenolate mofetil; pharmacokinetics; transplantation;
D O I
10.1253/circj.71.1022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The purpose of the study was to characterize the pharmacokinetics of mycophenolic acid (MPA) in Japanese heart transplant recipients and to find the time point that has the best correlation with the MPA area under the plasma concentration curve (AUC). Methods and Results Twenty-two Japanese recipients treated with mycophenolate mofetil were evaluated in the study. Approximately 9 months after transplantation, the area under the MPA serum concentration-time curve from 0 to 12h (AUC(0-12h)) was evaluated. The MPA AUC(0-12h) values in the cyclosporine (CsA) and tacrolimus (FK) groups ranged from 13.11 to 50.98 mu g center dot h/ml and from 39.19 to 93.18 mu g center dot h/ml, respectively. Fourteen models were developed and analyzed for their ability to estimate the MPA AUC(0-12h) based on a limited number of samples in the CsA group. Sixteen models were developed in the FK group. The best model for predicting the full MPA AUC(0-12h) in the CsA group was a 3-time-point model that included C-0h, C-1h and C-2h (r(2), 0.96; mean prediction error, 0. 15 +/- 7.85%); a 2-time-point model that included C-0h, and C-2h (r(2), 0.94; mean prediction error, 0.495 +/- 10.35%) was also reliable. In the FK group, a 3-time-point model that included C-1h, C-2h and C-4h (r(2), 0.73; mean prediction error, 2.73 +/- 17.09%) was the best model for predicting the full MPA AUCo-12h, but it was not reliable in clinical practice. Conclusion A 3- (C-0h, C-1h and C-2h) and a 2-time-point model (C-0h and C-2h) are useful for predicting the full MPA AUC(0-12h) in Japanese heart transplant recipients treated with CsA but not with FK.
引用
收藏
页码:1022 / 1028
页数:7
相关论文
共 50 条
  • [21] Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy
    Chantal Le Guellec
    Matthias Büchler
    Bruno Giraudeau
    Yannick Le Meur
    Jean-Emmanuel Gakoué
    Yvon Lebranchu
    Pierre Marquet
    Gilles Paintaud
    [J]. European Journal of Clinical Pharmacology, 2002, 57 : 805 - 811
  • [22] Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase
    Yao, Xi
    Huang, Hongfeng
    Wei, Chunchun
    Chen, Ying
    Peng, Wenhan
    Xie, Wenqing
    Chen, Jianghua
    [J]. THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 516 - 523
  • [23] Does Tacrolimus, in Comparison With Sirolimus, Increase Mycophenolic Acid Exposure in Kidney Transplant Recipients?
    Picard, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (06) : 650 - 651
  • [24] Estimation of the area under the curve for mycophenolic acid in adult renal transplant patients with concomitant tacrolimus using a limited sampling strategy
    Teshima, D.
    Maiguma, T.
    Kaji, H.
    Otsubo, K.
    Kitagawa, N.
    Okabe, Y.
    Sugitani, A.
    Tanaka, M.
    Oishi, R.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (02) : 159 - 163
  • [25] Early Phase Limited Sampling Strategy Characterizing Tacrolimus and Mycophenolic Acid Pharmacokinetics Adapted to the Maintenance Phase of Renal Transplant Patients
    Miura, Masatomo
    Satoh, Shigeru
    Niioka, Takenori
    Kagaya, Hideaki
    Saito, Mitsuru
    Hayakari, Makoto
    Habuchi, Tomonori
    Suzuki, Toshio
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (04) : 467 - 474
  • [26] Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus
    Pawinski, T
    Hale, M
    Korecka, M
    Fitzsimmons, WE
    Shaw, LM
    [J]. CLINICAL CHEMISTRY, 2002, 48 (09) : 1497 - 1504
  • [27] Simultaneous limited blood sampling models for tacrolimus and mycophenolic acid provide an accurate area under the curve prediction for kidney transplant recipients
    Nishikawa, Kouhei
    Kato, Manabu
    Yoshio, Yuko
    Hasegawa, Yoshihiro
    Kanda, Hideki
    Kanai, Masahiro
    Arima, Kiminobu
    Enokiya, Tomoyuki
    Muraki, Yuichi
    Iwamoto, Takuya
    Okuda, Masahiro
    Sugimura, Yoshiki
    [J]. TRANSPLANTATION, 2016, 100 (07) : S165 - S165
  • [28] Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area under the Concentration-Time Curve Treated in Japanese Living-Related Renal Transplant Recipients with Concomitant Extended-Release Tacrolimus
    Yamaguchi, Kazunori
    Fukuoka, Noriyasu
    Kimura, Sumio
    Watanabe, Masahiro
    Tani, Kumiko
    Tanaka, Hiroaki
    Sofue, Tadashi
    Kosaka, Shinji
    Inui, Masashi
    Kakehi, Yoshiyuki
    Houchi, Hitoshi
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (06) : 1036 - 1039
  • [29] VALIDATION OF LIMITED SAMPLING STRATEGIES FOR ESTIMATION OF TACROLIMUS AUC IN PEDIATRIC HEART TRANSPLANT RECIPIENTS
    Sid-Otmane, L.
    Antczak, C.
    Kassir, N.
    Raboisson, M.
    Lapeyraque, A.
    Theoret, Y.
    Litalien, C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S109 - S109
  • [30] Comparison of 3 Estimation Methods of Mycophenolic Acid AUC based on a Limited Sampling Strategy in Renal Transplant Patients
    Hulin, Anne
    Blanchet, Benoit
    Audard, Vincent
    Barau, Caroline
    Furlan, Valerie
    Durrbach, Antoine
    Taieb, Fabrice
    Lang, Philippe
    Grimbert, Philippe
    Tod, Michel
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (02) : 224 - 232